← Back to Clinical Trials
Recruiting NCT07396051

NCT07396051 Rehabilitation Exercise Against Complications in High-risk Elderly After Lumbar Fusion(REACH)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07396051
Status Recruiting
Phase
Sponsor Xuanwu Hospital, Beijing
Condition Adjacent Segment Degeneration
Study Type INTERVENTIONAL
Enrollment 212 participants
Start Date 2026-01-25
Primary Completion 2028-03-01

Eligibility & Interventions

Sex All sexes
Min Age 75 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Postoperative Multimodal Rehabilitation Program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 212 participants in total. It began in 2026-01-25 with a primary completion date of 2028-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a prospective, randomized controlled trial aimed at evaluating whether a structured multimodal rehabilitation program can delay or reduce the occurrence of adjacent segment degeneration (ASDeg) in frail elderly patients after short-segment lumbar fusion surgery.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 75 years. * Classified as "frail" according to the Fried frailty phenotype. * Scheduled for first-time, posterior short-segment (1-2 levels) lumbar instrumented fusion surgery. * Willing and able to provide written informed consent and complete the 2-year follow-up. Exclusion Criteria: * History of previous lumbar spine surgery. * Lumbar pathology due to tumor, trauma, infection, or congenital deformity. * Comorbidities with a severe impact on prognosis or ability to participate in rehabilitation (e.g., severe cardiopulmonary disease, advanced dementia).

Contact & Investigator

Central Contact

Lu Shibao, MD.

✉ 1831327488@qq.com

📞 18310031517

Frequently Asked Questions

Who can join the NCT07396051 clinical trial?

This trial is open to participants of all sexes, aged 75 Years or older, studying Adjacent Segment Degeneration. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07396051 currently recruiting?

Yes, NCT07396051 is actively recruiting participants. Contact the research team at 1831327488@qq.com for enrollment information.

Where is the NCT07396051 trial being conducted?

This trial is being conducted at Beijing, China, Beijing, China, Beijing, China.

Who is sponsoring the NCT07396051 clinical trial?

NCT07396051 is sponsored by Xuanwu Hospital, Beijing. The trial plans to enroll 212 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology